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Abstract 
Naturally occurring lactams, such as the polyketide-derived macrolactams, provide a diverse class of 
natural products that could enhance existing chemically produced lactams. While β-amino acid loading in 
the fluvirucin B2 polyketide pathway has been proposed by a previously identified putative biosynthetic 
gene cluster, biochemical characterization of the complete loading enzymes has not been described. Here 
we elucidate the complete biosynthetic pathway of the β-amino acid loading pathway in fluvirucin B2 
biosynthesis. We demonstrate the promiscuity of the loading pathway to utilize a range of amino acids 
and further illustrate the ability to introduce non-native acyl transferases to selectively transfer β-amino 
acids onto a PKS loading platform. The results presented here provide a detailed biochemical description 
of β-amino acid selection and will further aid in future efforts to develop engineered lactam-producing 
PKS platforms. 
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 Lactams are an important class of chemicals used in the production of polymers, pharmaceuticals, and 
insecticides.[1–5]  In nature, the polyketide-derived macrolactams are a clade of natural products containing 
unique β-amino acids as part of the core macrolide structure.[6] Notable macrolactams include the 
fluvirucins, rifamycin and  geldanamycin. [4,7,8] Fluvirucin B2 is a 14-membered macrolactam that shows 
both antifungal and antiviral activity,[4,9] and one of the main structural features of fluvirucin B2 is the β-
alanine starter unit of the polyketide skeleton (Figure 1). The biosynthetic nature of polyketide synthases 
and their potential to be re-programmed could enhance existing chemically produced lactams analogs, 
such as valerolactam, caprolactam, and laurolactam (Figure 1). Previous work on the origin of the β-
alanine moiety in fluvirucin B2 suggests it originates from L-aspartate via decarboxylation of its α-
carboxyl group.[3] More recently, the putative biosynthetic gene cluster of fluvirucin B2 from 
Actinomadura fluva subsp. indica ATCC 53714 and its corresponding β-amino acid loading pathway 
were annotated.[10] In this presumptive fluvirucin B2 loading pathway, L-aspartate is first activated by the 
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adenylation enzyme FlvN and ligated with the standalone acyl carrier protein (ACP) FlvL to give 
aspartyl-ACP (1) (Figure 1). Then, the pyridoxal-phosphate (PLP)-dependent decarboxylase FlvO 
removes the α-carboxy group of the aspartyl-FlvL (1), resulting in a β-alanyl-FlvL intermediate (2). It has 
been proposed that the resulting β-alanyl-FlvL (2) is further aminoacylated with L-alanine by another 
adenylation enzyme, FlvM, to give a dipeptidyl-FlvL (3). The dipeptidyl-FlvL intermediate is then 
transferred to the loading ACP domain of the fluvirucin polyketide synthase (PKS) FlvP1 (4) by the 
amino acyltransferase (AT) FlvK (Figure 1, Figure S1).[10] Similar loading pathways have been proposed in 
other β-amino acid priming PKS products, such as vicenistatin and sceliphrolactam. [11–13] In our efforts to 
understand the entire biochemical pathway, all Flv enzymes and related homologs were expressed in 
Escherichia coli as N-terminal His6-tagged proteins from codon-optimized synthetic genes (Figure S2, 
Table S1) and reconstituted in vitro. All ACP-tethered intermediates were initially monitored via MALDI 
TOF, as it allowed us to robustly test a wide range of substrates and conditions with accurate resolution 
on the entire ACP. Here, we describe the results from each biochemical step in order, as depicted in 
Figure 1. 
  
At the first step of β-amino acid loading, Miyanaga and coworkers proposed selection of L-aspartate by 
the ATP-dependent adenylation enzyme FlvN, which ligates the amino acid onto the stand-alone ACP 
FlvL to generate aspartyl-FlvL (1).[10] We reconstituted FlvN, FlvL with all the necessary cofactors in the 
presence of 2mM L-aspartate. The mass corresponds to aspartyl-FlvL (1) (Figure 2A-B). This initial 
experiment supported the previously proposed selectivity of FlvN for L-aspartate and provided direct 
evidence of the aspartyl-FlvL (1) intermediate. We repeated the same experiment and tested a variety of 
amino acids, dicarboxylic acids and ω-amino fatty acids at the same 2 mM concentration (Figure 2C). 
Surprisingly, we also observed FlvN selectivity for L-asparagine and transfer to FlvL (Figure 2B, Table 
S2) with a comparable mass shift to the aspartyl-FlvL (1) in our initial experiment with L-aspartate 
(Figure 2B, Table S2). This suggested that L-asparagine selection and ligation to FlvL by the adenylating 
enzyme FlvN produced the same aspartyl-FlvL (1) intermediate. To further test this hypothesis, we 
introduced the second enzyme in the pathway, the PLP-dependent decarboxylase FlvO.  It has been 
proposed that FlvO removes the α-carboxy group of the aspartyl-ACP (1), resulting in a β-alanyl-ACP 
intermediate (2). If both L-aspartate and L-asparagine are activated and ligated to FlvL to form the same 
aspartate-FlvL (1) intermediate, decarboxylation by FlvO would be equally observed with either starting 
amino acid and display the same mass shift. To this end, we introduced the FlvO to the reactions 
containing either L-aspartate or L-asparagine. Both reactions displayed a mass shift corresponding to the 
β-alanyl-ACP intermediate (2), indicating successful decarboxylation by FlvO (Figure 2A-B, Table S2). 
These results further supported our hypothesis that both L-aspartate and L-asparagine can be selected by 
FlvN to generate the same aspartate-FlvL (1) intermediate, which is subsequently decarboxylated by 
FlvO. 
  
As both L-aspartate and L-asparagine could be utilized by FlvN, we next investigated the substrate 
preference and catalytic properties of FlvN. Since FlvN has an ATP-dependent adenylation domain, we 
anticipated that the FlvN-catalyzed reaction would require ATP hydrolysis to activate the amino acid 
prior to being transferred onto the 4’-phosphopantetheine of the holo-FlvL. We tested FlvN against L-
aspartate and L-asparagine by using an ATP-PPi release assay previously reported by Duckworth et al. 
and Wilson et al.[14,15] The ATP-PPi release assay allowed us to measure FlvN’s ability to activate L-
aspartate and L-asparagine with ATP. Overall, FlvN demonstrated much higher catalytic activity on L-
aspartate (kcat/Km = 221.27 min−1 mM−1 ) compared to L-asparagine (kcat/Km = 1.165 min−1 mM−1)  (Table 1, 
Figure S4A). These results suggest L-aspartate is the preferred amino acid in the fluvirucin β-amino acid 
loading pathway.   
  
We then focused on testing aminoacylation of the β-alanyl-FlvL (2) intermediate by the ATP-
dependent FlvM. It has been proposed that the β-alanyl-ACP (2) is further aminoacylated with L-alanine 
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to give a dipeptidyl-ACP intermediate (3). Using the same in vitro reconstitution strategy in parallel with 
MALDI TOF, we reconstituted 2 mM L-aspartate with FlvL, FlvN, FlvO, FlvM in the presence of various 
amino acids and short chain acids (Figure 3A-C). FlvM demonstrated substrate promiscuity, 
aminoacylating the β-alanyl-FlvL (2) intermediate with L-alanine (3a), L-serine (3b) and glycine (3c) 
(Figure 3). Partial aminoacylation was also observed with L-leucine and L-isoleucine (Figure 3C, Figure 
S3J-K). A closer inspection at the substrate preference of FlvM by leveraging the previously mentioned 
ATP-PPi release assay, demonstrated preference for L-alanine (kcat/Km = 57.78 min−1 mM−1 ) followed by L-
serine (kcat/Km = 3.69 min−1 mM−1 ) and glycine (kcat/Km = 1.77 min−1 mM−1 ) (Table 1, Figure S4B). Both 
MALDI TOF and the ATP-PPi release assays of FlvM suggest L-alanine as the preferred substrate over 
other amino acids. Unexpectedly, FlvM displays a large amino acid substrate flexibility, which has never 
been described in this type of β-amino acid loading pathway. 
  
The final step in β-amino acid loading pathway is the AT-catalyzed transfer of the dipeptidyl from FlvL 
onto the loading ACP from the fluvirucin PKS (FlvP1 ACPL). In the fluvirucin B2 pathway, the putative 
AT (FlvK) has been proposed to conduct such transfer.[10] However, a closer inspection at the FlvK 
(GenBank: BAV56001.1) sequence suggest FlvK contains an AMP binding domain and is closely related 
to adenylate-forming domains (AFD) class 1 superfamily. This was further supported by the lack of 
transfer observed in our in vitro reconstitution experiments of FlvK. A closer inspection at the nucleotide 
sequence of the fluvirucin biosynthetic gene cluster using antiSMASH revealed a stand-alone AT, as 
predicted by Miyanaga et al.[10,16,17] To this end, we cloned and expressed the newly annotated FlvK (FlvK*). 
We reconstituted the entire β-amino acid pathway with FlvK*, FlvP1 ACPL and monitored dipeptidyl 
transfer from the FlvL to the FlvP1 ACPL. The native FlvK* displayed promiscuity to transfer all three 
dipeptide intermediates from FlvL to the FlvP1 ACPL. The dipeptidyl-FlvL intermediate with L-alanine 
(3a), L-serine (3b), and glycine (3c) were transferred to the FlvP1 ACPL, generating (4a), (4b), and (4c) 
(Figure 4A-B, Table S3). Partial transfer by FlvK* was observed with the unprotected β-alanyl (2) FlvL 
intermediate (Figure S5). 
  
In addition, we aimed to test the compatibility of non-native ATs to transfer the various FlvL 
intermediates, primarily the unprotected β-alanyl (2) FlvL intermediate. We focused on the previously 
identified AT homologs from the vicenistatin pathway (VinK) and the sceliphrolactam pathway (SceG) 
(Figure S7C).[11–13] Similar to FlvK*, the  AT SceG from sceliphrolactam biosynthesis demonstrated 
promiscuity to transfer all three dipeptide intermediates from the FlvL to the FlvP1 ACPL (Figure 4, Figure 
S5). Surprisingly, the AT VinK from vicenistatin biosynthesis demonstrated selectivity not only for the L-
alanine aminoacylated (3a) but the unprotected β-alanyl (2) FlvL intermediates as well (Figure 4, Table 
S3, Figure S5). VinK selectively transferred both of these intermediates to generate (4a) and (4d). These 
results illustrate the flexibility of non-native AT domains to be compatible in the fluvirucin biosynthetic 
pathway. Equally important, these results demonstrate AT’s from SceG and VinK to be selective towards 
different ACP-tethered intermediates, providing key gatekeeping insights into β-amino acid priming in 
lactam producing PKSs. 
   
Having biochemically characterized the Flv β-amino acid loading enzymes on the stand-alone FlvL ACP, 
we wanted to investigate if the FlvL ACP could be bypassed and all loading/modifications could be 
directly accomplished on the PKS-tethered loading FlvP1 ACPL. The stand-alone FlvL ACP and the 
FlvP1 ACPL share a sequence similarity of 71.9% in a 32-amino acid overlap region where the conserved 
“DSL” motif is located (Figure S7D). To this end, we reconstituted FlvN, 2mM L-aspartate and replaced 
the stand-alone FlvL with an excised version of FlvP1 ACPL. The reaction was monitored for L-aspartate 
addition via MALDI TOF at various time points (Figure S6). Given that almost complete conversion of 
holo-FlvL to aspartyl-FlvL (1) by FlvN was observed at an hour time point, this was utilized as a point of 
reference. Partial loading of L-aspartate by FlvN onto the  FlvP1 ACPL was observed after an 8 hour 
incubation. The majority of the FlvP1 ACPL , was present in the holo form, suggesting a lower efficiency 
by FlvN to transfer the L-aspartate to the loading ACP. No aspartate decarboxylation was observed in the 
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presence of FlvO. This evidence suggests that the stand-alone FlvL is required for adequate L-aspartate 
loading and processing prior to being transferred on to the FlvP1 ACPL . Moreover, it provides evidence 
that other factors, such as FlvN and FlvL protein-protein interactions, may play an important role. 
  
In this report, we present a detailed biochemical description of β-amino acid selection, incorporation and 
promiscuity in the fluvirucin B2 loading pathway. The loading pathways ability to utilize various amino 
acids as starter units and aminoacylating groups provides new insights into the flexibility of β-amino acid 
selection in polyketide biosynthesis. The range of amino acids that can be utilized in the β-amino acid 
loading platform presented in this study provides a roadmap for future metabolic engineering efforts to 
establish a host with the appropriate amino acid precursor pools. Moreover, this work illustrates the 
ability to mix-and-match compatible AT domains for selective β-amino acid transfer on to a native or 
potentially engineered PKS. With a growing interest in the renewable production of lactams, a broader 
understanding of β-amino acid selection in naturally existing macrolactam biosynthetic pathways will 
further aid in future efforts to develop engineered lactam-producing PKS platforms. 
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Table 1. Steady-state kinetic parameters of FlvN and FlvM.  
Enzyme Substrate Km (mM) kcat (min-1) kcat/Km 
 (min-1/mM-1) 
FlvN L-aspartate 0.055 ± 0.006 12.17 ± 0.22 221.27 
FlvN L-asparagine 6.64 ± 1.05 10.96 ± 0.49 1.165 
FlvM L-alanine 0.189 ± 0.024 10.95 ± 0.23 57.78 
FlvM L-serine 2.749 ± 0.429 10.15 ± 0.38 3.69 
FlvM glycine 10.69 ± 1.42 18.92 ± 0.79 1.77 
 
 
 
 
Figure 1. β-amino acid loading platform involved in fluvirucin B2 biosynthesis.  
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Figure 2. A) Schematic representation of FlvN activation and transfer of L-aspartate and L-asparagine onto FlvL 
and subsequent decarboxylation by FlvO and B) the corresponding MALDI TOF traces of the FlvL modifications. 
C) A list of the various substrates tested.   
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Figure 3. A) Schematic representation of FlvM aminoacylation of the β-alanyl-FlvL intermediate (2) and B) the 
corresponding MALDI TOF traces of the FlvL modifications. C) A list of the various substrates tested with FlvM. 
Partial aminoacylation was also observed with L-leucine and L-isoleucine (yellow), as depicted by the MALDI TOF 
traces in Figure S3J-K.  
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Figure 4. A) Schematic representation of dipeptide transfer from FlvL to the FlvP1 ACP by the native FlvK*, the 
non-native acyl transferases VinK and SceG. B) The corresponding MALDI TOF traces focused on the FlvP1 ACP. 
VinK also transfers 3a to generate 4a as depicted in Figure S5. The non-native acyl transferase SceG also selectively 
transfers intermediates 3a-c to generate 4a-c. MALDI TOF traces for SceG and VinK that are in parenthesis can be 
found in Figure S5.  
 
 
 
 
 
 
S
O
NH2
FlvL
FlvM
ATP
AMP +
PPi
amino
acidv
2
O
NH
O
S
NH2
NH2
OH
O
NH
O
S
NH2
O
NH
O
S
B
ACPL
SH
Mass (m/z)
0
20
40
60
80
100
%
 I
n
te
n
s
it
y
14997.0 15312.4 15627.8 15943.2
*
*
*
*
4a
4b
4c
S
O
NH2
*
NH
O
S
R
3a-c
A
VinK
FlvL
FlvK*, 
(SceG, VinK)
FlvL
4d
FlvL
ACPL
ACPL
ACPL
ACPL
Control
15463.0205
0
20
40
60
80
100
%
 I
n
te
n
s
it
y
14997.0 15312.4 15627.8 15943.2
15530.3428
0
20
40
60
80
100
%
 I
n
te
n
s
it
y
14997.0 15312.4 15627.8 15943.2
15601.0010
0
20
40
60
80
100
%
 I
n
te
n
s
it
y
14997.0 15312.4 15627.8 15943.2
15620.7080
0
20
40
60
80
100
%
 I
n
te
n
s
it
y
14997.0 15312.4 15627.8 15943.2
15588.4355
FlvK*, 
(SceG)
FlvK*, 
(SceG)
L-ala
L-ser
gly
10.1002/cbic.201800169
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
  
References 
 
[1]  M. Winnacker, J. Sag, A. Tischner, B. Rieger, Macromol. Rapid Commun. 2017, 38, DOI 
10.1002/marc.201600787. 
[2]  J. Zhang, J. F. Barajas, M. Burdu, G. Wang, E. E. Baidoo, J. D. Keasling, ACS Synth. Biol. 
2017, 6, 884–890. 
[3]  M. S. Puar, V. Gullo, I. Gunnarsson, V. Hegde, M. Patel, J. Schwartz, Bioorg. Med. Chem. Lett. 
1992, 2, 575–578. 
[4]  K. Tomita, N. Oda, Y. Hoshino, N. Ohkusa, H. Chikazawa, J. Antibiot. 1991, 44, 940–948. 
[5]  M. Kimura, H. Ishihara, S. Kato, Arch. Pharm. Res. 2007, 30, 938–944. 
[6]  F. Kudo, A. Miyanaga, T. Eguchi, Nat. Prod. Rep. 2014, 31, 1056–1073. 
[7]  P. R. August, L. Tang, Y. J. Yoon, S. Ning, R. Müller, T. W. Yu, M. Taylor, D. Hoffmann, C. 
G. Kim, X. Zhang, et al., Chem. Biol. 1998, 5, 69–79. 
[8]  L. Vetcher, Z.-Q. Tian, R. McDaniel, A. Rascher, W. P. Revill, C. R. Hutchinson, Z. Hu, Appl. 
Environ. Microbiol. 2005, 71, 1829–1835. 
[9]  T.-Y. Lin, L. S. Borketey, G. Prasad, S. A. Waters, N. A. Schnarr, ACS Synth. Biol. 2013, 2, 
635–642. 
[10]  A. Miyanaga, Y. Hayakawa, M. Numakura, J. Hashimoto, K. Teruya, T. Hirano, K. Shin-Ya, F. 
Kudo, T. Eguchi, Biosci. Biotechnol. Biochem. 2016, 80, 935–941. 
[11]  A. Miyanaga, S. Iwasawa, Y. Shinohara, F. Kudo, T. Eguchi, Proc Natl Acad Sci USA 2016, 
113, 1802–1807. 
[12]  Z. J. Low, L. M. Pang, Y. Ding, Q. W. Cheang, K. Le Mai Hoang, H. Thi Tran, J. Li, X.-W. Liu, 
Y. Kanagasundaram, L. Yang, et al., Sci. Rep. 2018, 8, 1594. 
[13]  Y. Shinohara, F. Kudo, T. Eguchi, J. Am. Chem. Soc. 2011, 133, 18134–18137. 
[14]  B. P. Duckworth, D. J. Wilson, C. C. Aldrich, Methods Mol. Biol. 2016, 1401, 53–61. 
[15]  D. J. Wilson, C. C. Aldrich, Anal. Biochem. 2010, 404, 56–63. 
[16]  K. Blin, M. H. Medema, D. Kazempour, M. A. Fischbach, R. Breitling, E. Takano, T. Weber, 
Nucleic Acids Res. 2013, 41, W204-12. 
[17]  T. Weber, K. Blin, S. Duddela, D. Krug, H. U. Kim, R. Bruccoleri, S. Y. Lee, M. A. Fischbach, 
R. Müller, W. Wohlleben, et al., Nucleic Acids Res. 2015, 43, W237-43. 
 
 
 
10.1002/cbic.201800169
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemBioChem
This article is protected by copyright. All rights reserved.
